Search
On the evening of March 24, BrightGene, a company listed on the Science and Technology Innovation Board, disclosed that its independently developed oral dual-target weight loss medication, BGM0504 tablets, had yielded positive outcomes in a Phase I clinical trial. This trial was carried out among participants from both China and the United States, focusing on the treatment of overweight and obesity in adults. Serving as a dual agonist for GLP-1 and GIP receptors, this drug falls under the category of Class 1 innovative chemical medicine, which has not yet been commercialized either domestically or internationally. Preliminary clinical data indicated that, relative to the baseline, the average weight of participants in each dosage group decreased by 1.04% to 5.56% (least squares mean).
-
C114 Communication Network -
Communication Home
